RVMD 240517 36.00C (RVMD240517C36000) Stock Options, News & Quotes

US OptionsDetailed Quotes

RVMD240517C36000

Watchlist

4.20
0.000.00%

15min DelayTrading May 6 12:33 ET

0.00High0.00Low

Intraday

News

Earnings Call Summary | Revolution Medicines(RVMD.US) Q1 2024 Earnings Conference
The following is a summary of the Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript:Financial Performance:Revolution Medicines reported a net loss of $116.0 million or $0.70 per share
moomoo AI12:05 ET · Conference Call
Revolution Medicines Is Maintained at Outperform by Wedbush
Revolution Medicines Is Maintained at Outperform by Wedbush
Dow JonesMay 9 08:57 ET
Revolution Medicines (RVMD) Receives a Buy From Piper Sandler
TipRanksMay 9 06:54 ET
Express News | Needham Reiterates Buy on Revolution Medicines, Maintains $46 Price Target
BenzingaMay 9 06:46 ET
Revolution Medicines Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 20.07% Needham → $46 Reiterates Buy → Buy 04/12/2024 17.46% Oppenheimer $43 → $45 Maintains Out
BenzingaMay 9 06:45 ET
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Revolution Medicines (RVMD) and Personalis (PSNL)
TipRanksMay 9 06:40 ET

Comments

Jerry Kronenberg

Apr 11 04:11

ColumnsRevolution Medicines Gains 10%+ on Word of Experimental Anti-Tumor Drug

$Revolution Medicines(RVMD.US)$ rose more than 10% Wednesday after the biotech firm reported the discovery and preclinical-to-clinical translation of its anti-tumor drug RMC-6236.
RVMD gained 10.6% to close at $36.50 on word of the experimental drug, which the company disclosed in the publication Cancer Discovery.
Revolution disclosed news of the drug on Tuesday shortly before the market closed, sending shares up 3.4% that da...